Shree Ganesh Bio-Tech (India) Limited

Basic Materials — Agricultural Inputs · BSE

₹0.46−₹0.01 (−2.13%)

DalalBaazaar Score

39 / 100

🔴 Weak

Verdict

CAUTION

Risk

Very High

Driven by negative free cash flow, the company is currently loss-making, micro-cap size, which brings thin liquidity.

In simple words: The company is currently losing money, with modest growth. Cash generation is currently the main factor to watch.

Decision support, not a buy or sell call.

As of 18 Oct 2026, 7:02 pm

Understanding the Business

Company site ↗

The 60-second version of Shree Ganesh Bio-Tech (India) Limited — what it does, how it earns, and who it competes with, before any of the numbers below.

What does this company do?

Shree Ganesh Bio-Tech (India) Limited engages in plant tissue culture activities in India. The company engaged in trading seeds and bhushi.

IndustryAgricultural Inputs

SectorBasic Materials

Employees5

Annual revenue₹5 Cr

How does it make money?

Turns over ₹5 Cr a year. Of every ₹100 of sales, about ₹8 reaches shareholders as profit, with ₹17 left at the operating level before interest, tax and depreciation. Each of its 5 employees supports ₹99.4 lakh of revenue a year, the signature of a people-led business.

Revenue / employee₹99.4 lakh

Who are its competitors?

The closest listed comparisons in its industry are TATA STEEL LIMITED, JSW STEEL LIMITED, ULTRATECH CEMENT LIMITED, ASIAN PAINTS LIMITED. These are the companies its valuation and returns are measured against elsewhere in this report.

Compared side by side in Peers ↓

What is its competitive advantage?Little sign of one

Returns on capital of 0.8% are at or below what the capital likely costs. That is the financial pattern of a business competing largely on price, where advantage has to come from execution rather than position.

Peer median ROE22.3%

What has been driving growth?

Sales and margins have both contributed to where profit is now. Over 3 years revenue moved -92% while net margin moved +133% relative to itself. What this cannot tell you is which products, customers or geographies did the work — that lives in the segment disclosures of the annual report.

Revenue effect-92%

Margin effect+133%

DalalBaazaar Score

39/ 100

Weak

Weighted across six categories. Every point is explained below.

✗ Revenue has contracted at 57.0% a year
✗ Profit has declined at 43.0% a year

Quality vs. Valuation

Company Quality

29/ 100

Weak

How good the business is, ignoring the share price entirely.

Valuation

52/ 100

Fair

What you are being asked to pay, ignoring how good the business is.

Weak on business quality and not cheap enough to compensate.

vs. its own history

Not enough price and earnings history

vs. sector peers

Not enough peers with a usable P/E

vs. generic bands

No P/E available

EV/EBITDA

22.0x

PEG

—

What's Good / What's Bad

🟢 What's Going Well2

Margins are improving
EBITDA margin is up from 4.0% to 16.7% over 3 years.
Consistently profitable
Profitable in every one of the last 4 reported years.

🔴 What Needs Attention1

Return on capital is falling
ROCE has declined from 4.4% to 0.8% — often a sign of competition or overexpansion.

Red Flags

3 items require attention · 3 watch

🟡Free cash flow is negativeFinancial
Free cash flow was -₹8 Cr in the latest year.
🟡Profit is decliningFinancial
Net profit is down 81% over 3 years.
🟡Low reported insider holdingOwnership
Reported insider holding is 2.5%. For Indian companies this field is an unreliable proxy — check the official promoter shareholding in the exchange filing.

Investment Thesis

🟢 Bull CaseWhat could make this work?

Margin expansion has further to run
EBITDA margin has risen from 4.0% to 16.7%. If that holds, profit compounds faster than sales and today's multiple looks cheaper in hindsight than it does now.
Earnings have proved durable
Profitable in every one of the last 4 reported years. Consistency lowers the risk that any single bad year is structural rather than cyclical.

🔴 Bear CaseWhat could go wrong?

Size brings its own risk
Micro Cap businesses are thinly traded, so exits are harder in a falling market and single events move the price more than they would for a larger company.

🟡 Key Things to WatchMeasurable tripwires, set against where this company stands today

1EBITDA margin holds above 15%✓ 16.7%
Two points below today's level — enough room for noise, tight enough to catch real compression.
2Free cash flow remains positive✗ -₹8 Cr
Profit that never becomes cash eventually stops being profit.
3ROCE stays above 8%✗ 0.8%
Falling returns on capital are usually competition arriving, and show up here before they reach the margin.

Investment Checklist

4 / 9 checks passed

✗ Strong return on equity (ROE ≥ 15%)
✗ Strong return on capital employed (ROCE ≥ 15%)
✗ Healthy net margin (≥ 10%)
✗ Generates positive free cash flow
✓ Adequate short-term liquidity (Current Ratio ≥ 1.0)
✓ Revenue growing year-over-year
✓ Profit growing year-over-year
✓ Not buying right at the 52-week high
✗ Short-term technical trend isn't bearish

Price history

Quick Metrics

2 good · 5 neutral · 4 weak

Market Cap

₹18 Cr

Micro Cap

Smaller company — thin liquidity and deep drawdowns are normal here

P/E (Trailing)

Not available

No data

Source didn't return this field

P/B Ratio

0.37x

Reasonable

Reasonable against the company's book value

EPS (TTM)

₹0

Loss-making

Negative earnings per share — the business is losing money

ROE

0.6%

Weak

Weak capital efficiency

ROCE

0.8%

Weak

Low return on total capital employed

Debt/Equity

Not available

No data

Source didn't return this field

Revenue Growth (YoY)

3.3%

Modest

Modest growth

Profit Growth (YoY)

35.6%

Healthy

Profits growing at a healthy clip

Dividend Yield

None

No dividend yield reported — usually means no payout, but verify if one was recently initiated

Free Cash Flow

-₹8 Cr

Cash burning

Spending more cash than the operations bring in

More Metrics

Operating Margin

-62.5%

Weak

Thin margins leave little room for error

Net Margin

-10.4%

Weak

Very little revenue reaches the bottom line

Current Ratio

70.22

Comfortable

Healthy short-term liquidity

Beta (vs Nifty)

0.88

Market-like

Moves roughly in line with the market

52W Range Position

Near low

Near its 52-week low

Technical Snapshot

SMA 20 / SMA 50

0.5 / 0.5

Bearish alignment (short < long)

Price vs SMA 200

Below

Long-term downtrend

RSI (14)

42.9

Neutral momentum

Financial Trend (4-Year)

Metric	FY23	FY24	FY25	FY26	3Y CAGR
Revenue	₹62 Cr	₹20 Cr	₹23 Cr	₹5 Cr	-57.0%
EBITDA	₹2 Cr	₹1 Cr	₹1 Cr	₹1 Cr	-30.5%
EBITDA Margin	4.0%	4.2%	5.8%	16.7%	—
PAT (Net Profit)	₹2 Cr	₹1 Cr	₹0 Cr	₹0 Cr	-43.0%
EPS	₹0.05	₹0.02	₹0.01	₹0.01	-41.5%
ROE	3.3%	1.0%	0.4%	0.6%	—
ROCE	4.4%	1.4%	0.6%	0.8%	—
Free Cash Flow	₹11 Cr	₹10 Cr	-₹10 Cr	-₹8 Cr	—

🔴 Revenue has shrunk at 57.0% a year over 3 years.

🔴 EBITDA has shrunk at 30.5% a year over 3 years.

🟢 EBITDA Margin has risen from 4.0% to 16.7% over 3 years (+12.8 pts).

🔴 PAT (Net Profit) has shrunk at 43.0% a year over 3 years.

🔴 EPS has shrunk at 41.5% a year over 3 years.

🔴 ROE has fallen from 3.3% to 0.6% over 3 years (-2.7 pts).

🔴 ROCE has fallen from 4.4% to 0.8% over 3 years (-3.5 pts).

🔴 Free Cash Flow has turned negative, from ₹11 Cr to -₹8 Cr.

Balance Sheet & Cash Flow — FY2026

Total Assets

₹64 Cr

Total Liabilities

₹0 Cr

Total Debt

—

Cash & Equivalents

₹0 Cr

Operating Cash Flow

-₹8 Cr

Capex

—

Shareholding (proxy)

Institutional Holding

0.0%

Insider Holding

2.5%

Peer Comparison

Company	P/E	ROE
TATA STEEL LIMITED	19.8x	10.8%
JSW STEEL LIMITED	12.0x	24.7%
ULTRATECH CEMENT LIMITED	37.6x	11.1%
ASIAN PAINTS LIMITED	46.9x	22.3%

Recent News

3 mixed3 general

Shree Ganesh Biotech India Ltd Falls to 52-Week Low of Rs 0.44 as Sell-Off Deepens

MarketsMojo, 16 Oct

Shree Ganesh Bio Tech India : SUBMISSION OF RECONCILIATION OF SHARE CAPITAL AUDIT REPORT FOR THE QUARTER ENDED ON 30.09.2026.

www.marketscreener.com, 13 OctResults

🟡Mixed / dependsA results event. The figures on this page update once the new statements reach the data feed, which usually lags the announcement.

Shree Ganesh Bio-Tech closes trading window ahead of Q1FY27 results

scanx.trade, 12 JunResults

🟡Mixed / dependsA results event. The figures on this page update once the new statements reach the data feed, which usually lags the announcement.

Shree Ganesh Bio-Tech (India) Ltd. Share Price Live Today

CNBC TV18, 03 Jan

Shree Ganesh Biotech Q1 Results: Net loss widens to ₹57.32 lakh

scanx.trade, 04 AugResults

🟡Mixed / dependsA results event. The figures on this page update once the new statements reach the data feed, which usually lags the announcement.

Shree Ganesh Biotech (India) L Share Price

Upstox, 21 Mar

Watch Items

Trading very close to its 52-week low — worth checking whether this reflects a temporary setback or a structural problem.
Cross-check against the company's latest quarterly filing / investor presentation before acting.
2 metrics couldn't be retrieved for this stock — this is more common for smaller or thinly-covered listings.
Reported insider holding is low — cross-check the official promoter shareholding % in the company's exchange filing.

DalalBaazaar Thesis

StrongValuation

MiddlingFinancial Health

WeakBusiness Quality · Growth · Profitability · Risk

Points for each in the Score ↑

Weak on the fundamentals

Poor scores on business quality without a price low enough to compensate. There is no obvious argument for owning this over a stronger company at a similar valuation.

2 of 3 tripwires tripped — Free cash flow remains positive; ROCE stays above 8% · see Key things to watch ↑